Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
NCT ID: NCT01360645
Last Updated: 2015-11-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
826 participants
INTERVENTIONAL
2011-07-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase B
Drug: OPC-34712 + ADT
Drug: Placebo + ADT
OPC-34712 + ADT
Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
Placebo + ADT
Placebo + FDA Approved Antidepressant (ADT)
Phase A
Intervention: Drug: Placebo + ADT
Placebo + ADT
Placebo + FDA Approved Antidepressant (ADT)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OPC-34712 + ADT
Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
Placebo + ADT
Placebo + FDA Approved Antidepressant (ADT)
Placebo + ADT
Placebo + FDA Approved Antidepressant (ADT)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The current depressive episode must be equal to or greater than 8 weeks in duration
* Subjects must report a history for the current depressive episode of an inadequate response to no more than three adequate antidepressant treatments
Exclusion Criteria
* Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration.
* Subjects with a current Axis I (DSM-IV-TR) diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder
* Subjects with a clinically significant current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Arcadia, California, United States
Research Site
Beverly Hills, California, United States
Research Site
Fresno, California, United States
Research Site
Oceanside, California, United States
Research Site
San Diego, California, United States
Research Site
San Francisco, California, United States
Research Site
Sherman Oaks, California, United States
Research Site
Denver, Colorado, United States
Research Site
Norwalk, Connecticut, United States
Research Site
Coral Springs, Florida, United States
Research Site
Fort Myers, Florida, United States
Research Site
Hialeah, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Melbourne, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Prairie Village, Kansas, United States
Research Site
Wichita, Kansas, United States
Research Site
New Orleans, Louisiana, United States
Research Site
Shreveport, Louisiana, United States
Research Site
Belmont, Massachusetts, United States
Research Site
Boston, Massachusetts, United States
Research Site
Lincoln, Nebraska, United States
Research Site
New York, New York, United States
Research Site
Rochester, New York, United States
Research Site
Dayton, Ohio, United States
Research Site
Toledo, Ohio, United States
Research Site
Salem, Oregon, United States
Research Site
Allentown, Pennsylvania, United States
Research Site
Bala-Cynwyd, Pennsylvania, United States
Research Site
Bridgeville, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
San Antonio, Texas, United States
Research Site
Murray, Utah, United States
Research Site
Woodstock, Vermont, United States
Research Site
Richmond, Virginia, United States
Research Site
Seattle, Washington, United States
Research Site
Penticton, British Columbia, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Gatineau, Quebec, Canada
Research Site
Arcachon, , France
Research Site
Élancourt, , France
Research Site
Orvault, , France
Research Site
Palaiseau, , France
Research Site
Toulouse, , France
Research Site
Bełchatów, Poland, Poland
Research Site
Katowice, Upper Silesia, Poland
Research Site
Poznan, Woj. Wielkopolskie, Poland
Research Site
Gdynia, , Poland
Research Site
Kielce, , Poland
Research Site
Lublin, , Poland
Research Site
Tuszyn, , Poland
Research Site
Warsaw, , Poland
Research Site
Kosice-Barca, Slovakia, Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Levice, , Slovakia
Research Site
Michalovce, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kapadia S, Zhang Z, Ardic F, Patel M, Thase ME, Papakostas GI. Adjunctive brexpiprazole in patients with major depressive disorder who show minimal or partial response to antidepressant treatment: post hoc analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2025 Oct 7:pyaf074. doi: 10.1093/ijnp/pyaf074. Online ahead of print.
Ardic F, Zhang Z, Hogan M. Effects of adjunctive brexpiprazole in patients with major depressive disorder and sleep disturbance: a post hoc analysis of three randomized trials. Front Psychiatry. 2025 Aug 7;16:1618176. doi: 10.3389/fpsyt.2025.1618176. eCollection 2025.
Kapadia S, Zhang Z, Csoboth C, Patel M, Thase ME, Papakostas GI. Adjunctive brexpiprazole in patients with unresolved symptoms of depression on antidepressant treatment who are early in the disease course: post hoc analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2025 Aug 1;28(8):pyaf050. doi: 10.1093/ijnp/pyaf050.
McIntyre RS, Bubolic S, Zhang Z, MacKenzie EM, Therrien F, Miguelez M, Boucher M. Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of Three Placebo-Controlled Studies. J Clin Psychopharmacol. 2024 Mar-Apr 01;44(2):133-140. doi: 10.1097/JCP.0000000000001825.
Newcomer JW, Meehan SR, Chen D, Brubaker M, Weiss C. Changes in Metabolic Parameters and Body Weight in Patients With Prediabetes Treated With Adjunctive Brexpiprazole for Major Depressive Disorder: Pooled Analysis of Short- and Long-Term Clinical Studies. J Clin Psychiatry. 2023 Aug 28;84(5):23m14786. doi: 10.4088/JCP.23m14786.
McIntyre RS, Therrien F, Ismail Z, Meehan SR, Miguelez M, Larsen KG, Chen D, MacKenzie EM, Thase ME. Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data. J Psychiatr Res. 2023 Jun;162:71-78. doi: 10.1016/j.jpsychires.2023.04.012. Epub 2023 Apr 12.
Newcomer JW, Eriksson H, Zhang P, Meehan SR, Weiss C. Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies. J Clin Psychiatry. 2019 Oct 1;80(6):18m12680. doi: 10.4088/JCP.18m12680.
Hobart M, Zhang P, Weiss C, Meehan SR, Eriksson H. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale. Int J Neuropsychopharmacol. 2019 Mar 1;22(3):173-179. doi: 10.1093/ijnp/pyy095.
McIntyre RS, Weiller E, Zhang P, Weiss C. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials. J Affect Disord. 2016 Sep 1;201:116-23. doi: 10.1016/j.jad.2016.05.013. Epub 2016 May 12.
Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015 Sep;76(9):1224-31. doi: 10.4088/JCP.14m09688.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
331-10-228
Identifier Type: -
Identifier Source: org_study_id